Encapsulation of Triazole Derivatives Conjugated with Selenium Nanoparticles onto Nano-Chitosan for Antiproliferative Activity towards Cancer Cells

Document Type : Original Article


1 Polymers & Pigments Department, National Research Centre, 33 El-Buhouth St., Dokki, Cairo, Egypt

2 Photochemistry Department, Industrial Research Division, national research Centre, Dokki, Cairo, Egypt

3 photochemistry, NRC, Egypt, Cairo

4 Therapeutic Chemistry Dept. National Research Centre, Elbehouth St. Dokki, Giza, Egypt.

5 Photochemistry Department, National Research Centre, 33 El-Bohouth St., Dokki - 12622, Giza, Egypt


Encapsulation of synthesized triazole derivatives in the presence or absence of selenium nanoparticles (SeNPs) into nano-chitosan was directed to be employed in cancer treatment. The synthesized nano-capsules were well characterized using FTIR, TEM, SEM, DLS, and TGA. The results indicated that the nanoparticles exhibited a spherical shape with the size range of 80 nm as they were conjugated with triazole derivatives inside the capsules. These conjugated selenium nano-capsules showed enhanced thermal stability. The prepared Se nanoparticles were investigated for their anticancer activity and cytotoxicity toward the human colon cancer cell line (HCT116). The cytotoxicity and in vitro anticancer evaluation of the synthesized triazole derivatives loaded onto nano-chitosan through the samples (2a, 2b, 3a and 3b) have been assessed for human colon cancer cell line (HCT116). These samples are conjugated with selenium nanoparticles. They are loaded on nano-chitosan for the samples (3a and 3b) as well as nano-chitosan alone. The results showed that the in vitro antiproliferative activity of the newly synthesized compounds was significant and may be tested through further in vivo and pharmacokinetic studies.


Main Subjects

Volume 65, Issue 131 - Serial Number 13
Special Issue: Chemistry and Global Challenges (Part A)
December 2022
Pages 1231-1239
  • Receive Date: 28 June 2022
  • Revise Date: 12 July 2022
  • Accept Date: 24 July 2022